Medicare AdvantageAdministrativeLow impact
Tibsovo® (ivosidenib) (Revised)
Humana·Hematology, Oncology·Medicare Advantage
Effective date
Oct 22, 2025
We identified it
Aug 7, 2026
Summary
Humana Medicare Advantage updated its Tibsovo (ivosidenib) prior authorization policy on October 22, 2025, with no changes to coverage criteria or approval duration. This is a routine policy revision affecting IDH1-mutated AML, newly diagnosed AML, cholangiocarcinoma, and MDS. Billing teams should verify this is the current policy version before submitting prior authorization requests, as the document emphasizes online versions supersede printed copies.
Action Required
By October 29, 2025: Billing team must verify the current online version of this Tibsovo policy in Humana's system before submitting any prior authorization requests. Remove any printed or cached versions from reference materials and direct all staff to access the policy at https://dctm.humana.com/Mentor/Web/v.aspx?objectID=090009298a599c9f or Humana's official policy portal. No changes to prior authorization requirements or approval criteria have been implemented in this revision, so existing workflows remain valid. Document the verification date in your policy management system for compliance purposes.